References
- Tuthill RJ, Unger JM, Liu PY, Flaherty LE, Sondak VK, Southwest Oncology Group. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol 2002; 118:504-11; PMID: 12375635; http://dx.doi.org/10.1309/WBF7-N8KH-71KT-RVQ9
- Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008; 14:5220-27; PMID: 18698040; http://dx.doi.org/10.1158/1078-0432.CCR-08-0133
- Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-213; PMID: 12529460; http://dx.doi.org/10.1056/NEJMoa020177
- Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res 2001; 11:255-63; PMID: 11468514; http://dx.doi.org/10.1097/00008390-200106000-00007
- Ericsson C, Seregard S, Bartolazzi A, Levitskaya E, Ferrone S, Kiessling R, Larsson O. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci 2001; 42:2153-6; PMID: 11527924
- Blom DJ, Luyten GP, Mooy C, Kerkvliet S, Zwinderman AH, Jager MJ. Human leukocyte antigen class I expression: marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci 1997; 38:1865-72; PMID: 9286277
- Bröcker EB, Suter L, Brüggen J, Ruiter DJ, Macher E, Sorg C. Phenotypic dynamics of tumor progression in human malignant melanoma. Int J Cancer. 1985; 36:29-35; PMID: 3860479; http://dx.doi.org/10.1002/ijc.2910360106
- Durie FH, Campbell AM, Lee WR, Damato BE. Analysis of lymphocytic infiltration in uveal melanoma. Invest Ophthalmol Vis Sci 1990; 31:2106-10; PMID: 2211008
- Staibano S, Mascolo M, Tranfa F, Salvatore G, Mignogna C, Bufo P, Nugnes L, Bonavolontà G, De Rosa G. Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior? Int J Immunopathol Pharmacol 2006; 19:171-9; PMID: 16569355
- de Waard-Siebinga I, Hilders CG, Hansen BE, van Delft JL, Jager MJ. HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefes Arch Clin Exp Ophthalmol 1996; 234:34-42; PMID: 8750848; http://dx.doi.org/10.1007/BF00186516
- Meecham WJ, Char DH, Kaleta-Michaels S. Infiltrating lymphocytes and antigen expression in uveal melanoma. Ophthalmic Res 1992; 24:20-6; PMID: 1608588; http://dx.doi.org/10.1159/000267140
- Bronkhorst IH, Vu TH, Jordanova ES, Luyten GP, Burg SH, Jager MJ. Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest Ophthalmol Vis Sci 2012; 3:5370-8; PMID: 22743317; http://dx.doi.org/10.1167/iovs.11-9280
- Chen PW, Mellon JK, Mayhew E, Wang S, He YG, Hogan N, Niederkorn JY. Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion. Exp Eye Res 2007; 5:617-25; PMID: 17870068; http://dx.doi.org/10.1016/j.exer.2007.07.014
- Esser P, Grisanti S, Bartz-Schmidt K. TGF-beta in uveal melanoma. Microsc Res Tech 2001; 2:396-400; PMID: 11170298; http://dx.doi.org/10.1002/1097-0029(20010215)52:4%3c396::AID-JEMT1024%3e3.0.CO;2-V
- Lagouros E, Salomao D, Thorland E, Hodge DO, Vile R, Pulido JS. Infiltrative T regulatory cells in enucleated uveal melanomas. Trans Am Ophthalmol Soc 2009; 107:223-8; PMID: 20126498
- Mougiakakos D, Johansson CC, Trocme E, All-Ericsson C, Economou MA, Larsson O, Seregard S, Kiessling R. Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer 2010; 11:2224-33; PMID: 20209608
- Richmond A, Yang J, Su Y. The good and the bad of chemokineschemokine receptors in melanoma. Pigment Cell Melanoma Res 2009; 22:175-86; PMID: 19222802; http://dx.doi.org/10.1111/j.1755-148X.2009.00554.x
- Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69:3077-85; PMID: 19293190; http://dx.doi.org/10.1158/0008-5472.CAN-08-2281
- Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. J Clin Pathol 2007; 60:596-9; PMID: 16522748; http://dx.doi.org/10.1136/jcp.2005.032144
- Li H, Alizadeh H, Niederkorn JY. Differential expression of chemokine receptors on uveal melanoma cells and their metastases. Invest Ophthalmol Vis Sci 2008; 49:636-43; PMID: 18235009; http://dx.doi.org/10.1167/iovs.07-1035
- Scala S, Ieranò C, Ottaiano A, Franco R, La Mura A, Liguori G, Mascolo M, Staibano S, Ascierto PA, Botti G, et al. CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. Cancer Immunol Immunother 2007; 56:1589-95; PMID: 17410362; http://dx.doi.org/10.1007/s00262-007-0303-6
- Franco R, Botti G, Mascolo M, Loquercio G, Liguori G, Ilardi G, Losito S, La Mura A, Calemma R, Ierano C, et al. “CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression”. Front Biosci (Elite Ed) 2010; 2:13-21; PMID: 20036848; http://dx.doi.org/10.2741/e60
- Zitvogel L, Kepp O, Aymeric L, Ma Y, Locher C, Delahaye NF, André F, Kroemer G. Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy. Cancer Res 2010; 70:9538-43; PMID: 21098713; http://dx.doi.org/10.1158/0008-5472.CAN-10-1003
- de la Cruz PO, Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer 1990; 65:112-115; PMID: 2293857; http://dx.doi.org/10.1002/1097-0142(19900101)65:1%3c112::AID-CNCR2820650123%3e3.0.CO;2-X
- Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012; 72:917-27; PMID: 22186141; http://dx.doi.org/10.1158/0008-5472.CAN-11-1620
- Lucas CL, Workman CJ, Beyaz S, LoCascio S, Zhao G, Vignali DA, Sykes M. LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L. Blood 2011; 117:5532-40; PMID: 21422469; http://dx.doi.org/10.1182/blood-2010-11-318675
- Wilke CM, Wei S, Wang L, Kryczek I, Kao J, Zou W. Dual biological effects of the cytokines interleukin-10 and interferon-γ. Cancer Immunol Immunother 2011; 60:1529-41; PMID: 21918895; http://dx.doi.org/10.1007/s00262-011-1104-5
- Berner V, Liu H, Zhou Q, Alderson KL, Sun K, Weiss JM, Back TC, Longo DL, Blazar BR, Wiltrout RH, et al. IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med 2007; 13:354-60; PMID: 17334371; http://dx.doi.org/10.1038/nm1554
- Hallermalm K, Seki K, De Geer A, Motyka B, Bleackley RC, Jager MJ, Froelich CJ, Kiessling R, Levitsky V, Levitskaya J. Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J Immunol 2008; 180:3766-74; PMID: 18322182; http://dx.doi.org/10.4049/jimmunol.180.6.3766
- Werneck MB, Lugo-Villarino G, Hwang ES, Cantor H, Glimcher LH. T-bet plays a key role in NK-mediated control of melanoma metastatic disease. J Immunol 2008; 180:8004-10; PMID: 18523263; http://dx.doi.org/10.4049/jimmunol.180.12.8004
- Pietra G, Romagnani C, Manzini C, Moretta L, Mingari MC. The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors. J Biomed Biotechnol 2010; 2010:907092; PMID: 20634877; http://dx.doi.org/10.1155/2010/907092
- Hurks HM, Valter MM, Wilson L, Hilgert I, van den Elsen PJ, Jager MJ. Uveal melanoma: no expression of HLA-G. Invest Ophthalmol Vis Sci. 2001; 42:3081-4; PMID: 11726606
- Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol 2006; 7:354-9; PMID: 16550198; http://dx.doi.org/10.1038/ni1328
- Niederkorn JY. Emerging concepts in CD8(+) T regulatory cells. Curr Opin Immunol. 2008; 20:327-31; PMID: 18406591; http://dx.doi.org/10.1016/j.coi.2008.02.003
- Vlad G, Suciu-Foca N. Resurgence or emergence of CD8+ Ts. Hum Immunol 2008; 69:679-80; PMID: 19026353; http://dx.doi.org/10.1016/j.humimm.2008.10.010
- Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, Thompson TC, Old LJ, Wang RF. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007; 13:6947-58; PMID: 18056169; http://dx.doi.org/10.1158/1078-0432.CCR-07-0842
- Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P, Curiel T, Lange A, Zou W. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 2005; 65:5020-6; PMID: 15958543; http://dx.doi.org/10.1158/0008-5472.CAN-04-4043
- Attig S, Hennenlotter J, Pawelec G, Klein G, Koch SD, Pircher H, Feyerabend S, Wernet D, Stenzl A, Rammensee HG, et al. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 2009; 69:8412-9; PMID: 19843860; http://dx.doi.org/10.1158/0008-5472.CAN-09-0852
- Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC, Ménégaux F, Rosenzwajg M, Lemoine F, Klatzmann D, Taieb J. Identification of CD8+CD25+Foxp3 +suppressive T cells in colorectal cancer tissue. Gut 2009; 58:520-9; PMID: 19022917; http://dx.doi.org/10.1136/gut.2008.158824
- Anastassiou G, Coupland SE, Stang A, Boeloeni R, Schilling H, Bornfeld N. Expression of Fas and Fas ligand in uveal melanoma: biological implication and prognostic value. J Pathol 2001; 194:466-72; PMID: 11523055; http://dx.doi.org/10.1002/path.926
- Nagarkatti-Gude N, Bronkhorst IH, van Duinen SG, Luyten GP, Jager MJ. Cytokines and chemokines in the vitreous fluid of eyes with uveal melanoma. Invest Ophthalmol Vis Sci 2012; 53:6748-55; PMID: 22930720; http://dx.doi.org/10.1167/iovs.12-10123
- Kim JJ, Yang JS, Dentchev T, Dang K, Weiner DB. Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. J Interferon Cytokine Res 2000; 20:487-98; PMID: 10841077; http://dx.doi.org/10.1089/10799900050023906
- Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol 2001; 2:102-7; PMID: 11175801; http://dx.doi.org/10.1038/84205
- Zou W, Borvak J, Marches F. Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12. J Immunol 2000; 165:4388-96; PMID: 11035076; http://dx.doi.org/10.4049/jimmunol.165.8.4388
- van Deventer HW, O’Connor W, Jr, Brickey WJ, Aris RM, Ting JP, Serody JS. C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Res 2005; 65:3374-9; PMID: 15833871
- Joosten SA, van Meijgaarden KE, Savage ND, de Boer T, Triebel F, van der Wal A, de Heer E, Klein MR, Geluk A, Ottenhoff TH. Identification of a human CD8 +regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci USA 2007; 104:8029-34; PMID: 17483450; http://dx.doi.org/10.1073/pnas.0702257104
- Faunce DE, Stein-Streilein J. NKT cell-derived RANTES recruits APCs and CD8+ T cells to the spleen during the generation of regulatory T cells in tolerance. J Immunol 2002; 169:31-8; PMID: 12077225; http://dx.doi.org/10.4049/jimmunol.169.1.31
- Mellado M, de Ana AM, Moreno MC, Martínez C, Rodríguez-Frade JM. A potential immune escape mechanism by melanoma cells through the activation of chemokine-induced T cell death. Curr Biol 2001; 11:691-6; PMID: 11369232; http://dx.doi.org/10.1016/S0960-9822(01)00199-3
- Chen KJ, Lin SZ, Zhou L, Xie HY, Zhou WH, Taki-Eldin A, Zheng SS. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One 2011; 6:e24671; PMID: 21935436; http://dx.doi.org/10.1371/journal.pone.0024671
- Zerbini G, Colucci A, Maestroni A, Miserocchi E, Bandello F, Modorati G. Increased stromal cell-derived factor-1 concentration levels in aqueous from patients with uveal melanoma. Melanoma Res 2012; 22:98-9; PMID: 22228277; http://dx.doi.org/10.1097/CMR.0b013e32834e1f50
- Dunussi-Joannopoulos K, Zuberek K, Runyon K, Hawley RG, Wong A, Erickson J, Herrmann S, Leonard JP. Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responses. Blood 2002; 100:1551-8; PMID: 12176869
- Vianello F, Papeta N, Chen T, Kraft P, White N, Hart WK, Kircher MF, Swart E, Rhee S, Palù G, et al. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1CXCL12 induce tumor-specific T-cell chemorepulsion and escape from immune control. J Immunol 2006; 176:2902-14; PMID: 16493048; http://dx.doi.org/10.4049/jimmunol.176.5.2902
- Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347:1222-5; PMID: 8622452; http://dx.doi.org/10.1016/S0140-6736(96)90736-9
- Cipponi A, Wieers G, van Baren N, Coulie PG. Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol Immunother 2011; 60:1153-60; PMID: 21553145; http://dx.doi.org/10.1007/s00262-011-1026-2
- Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 2011; 23:286-92; PMID: 21185705; http://dx.doi.org/10.1016/j.coi.2010.11.013
- Goldberg MV, Drake CG. LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol 2011; 344:269-78; PMID: 21086108; http://dx.doi.org/10.1007/82_2010_114
- Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003; 63:8360-5; PMID: 14678997
- Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statist Soc B 1995; 57:289-300.